GlassScriptPhysician profile
Stephen S Salmieri
NPI 1407822745
$4,810.11
in general payments reported to CMS, 2019-2025
34 companies · $803 in 2025
The $803 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $884 · 2021: $494 · 2022: $324 · 2023: $273 · 2024: $662 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $703.32 | 2019-2025 | Lynparza |
| Glaxosmithkline, LLC. | $616.41 | 2020-2025 | Jemperli, Zejula |
| Clovis Oncology, INC. | $416.79 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $410.60 | 2019-2025 | Lynparza, Keytruda |
| Tesaro, INC. | $403.72 | 2019 | |
| Pfizer INC. | $357.49 | 2019-2025 | |
| Ethicon US, LLC | $232.21 | 2019-2021 | |
| Seagen INC. | $171.14 | 2021-2023 | Tivdak |
| Medtronic, INC. | $168.65 | 2024 | Interstim |
| Astellas Pharma US INC | $148.53 | 2024-2025 | Veozah |
| Conmed Corporation | $112.28 | 2019 | |
| Daiichi Sankyo INC. | $102.16 | 2019-2020 | |
| Dysis Medical, INC. | $82.42 | 2020-2022 | |
| Baxter Healthcare | $70.25 | 2021-2025 | Tisseel, Perclot |
| Eisai INC. | $68.57 | 2019-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $65.93 | 2024 | Arista Ah Flexitip |
| Kyowa Kirin, INC. | $65.41 | 2019-2020 | |
| Caris Mpi, INC. | $56.47 | 2025 | Mi Cancer Seek |
| Abbvie INC. | $55.42 | 2025 | |
| Biom'Up France Sas | $54.72 | 2020 | |
| Davol INC. | $51.41 | 2023-2024 | Arista Ah Flexitip |
| Shield Therapeutics INC | $43.12 | 2022 | |
| Fortovia Therapeutics, INC. | $41.46 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $40.38 | 2022-2025 | Myrisk |
| Boston Scientific Corporation | $38.67 | 2019-2025 | Bulkamid |
| Bayer Healthcare Pharmaceuticals INC. | $36.20 | 2019-2021 | |
| Amgen INC. | $35.64 | 2019-2020 | |
| Millicent US INC | $35.29 | 2019-2025 | Femring, Intrarosa |
| Vertex Pharmaceuticals Incorporated | $24.34 | 2025 | |
| Immunogen, INC. | $24.31 | 2023 | Elahere |
| Verastem, INC. | $22.44 | 2025 | Avmapki Fakzynja Co-Pack |
| Stryker Corporation | $22.07 | 2025 | Photonsaber F, Spy-Phi System |
| Intuitive Surgical, INC. | $20.80 | 2024 | |
| Aspira Women'S Health INC | $11.49 | 2024 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Salmieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.